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Melanin-radiolabeled molecules for targeted radionuclide therapy (TRT) provide a promising approach for the
treatment of pigmented melanoma. Among these radiolabeled molecules, the iodinated melanin-specific binding
molecule ([131I]ICF01012) has shown a significant antitumor effect on metastatic melanoma preclinical models.
We report herein that [131I]ICF01012 decreases the epithelial-mesenshymal transition-like (EMT-like) markers in
both in vivo and in vitro three-dimensional (3D) melanoma spheroid models. [131I]ICF01012 spheroids irradiation
resulted in reduced clonogenic capacity of all pigmented spheroids accompanied by increased protein expression
levels of phosphorylated H2A.X, p53 and its downstream target p21. In addition, [131I]ICF01012 treatment leads to
a significant increase of cell pigmentation as demonstrated in SK-MEL3 human xenograft model. We also showed
that [131I]ICF01012 decreases the size and the number of melanoma lung colonies in the syngeneic murine
B16BL6 in vivo model assessing its potentiality to kill circulating tumor cells. Taken together, these results indicate
that [131I]ICF01012 reduces metastatic capacity of melanoma cells presumably through EMT-like reduction and
cell differentiation induction.
Translational Oncology (2019) 12, 1442–1452Introduction
Melanoma, one of the deadliest forms of skin cancer, is a malignant
tumor that arises from melanocytes, the pigment melanin-producing
cells. Worldwide, approximately 80% of skin cancer-related deathsA
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hare due to melanoma, and unfortunately its incidence rate continues
to increase [1]. Today, it is well known that malignant melanoma
shows a high tendency to invade and metastasize. One of the
fundamental processes of melanoma tumor progression and metas-
tasis formation is a pseudo-like epithelial-mesenchymal transition
(EMT-like) as melanocytes cannot be considered as epithelial cells.
Indeed, EMT in cancer is frequently associated with poor prognosis.
This genetic program promotes loss of epithelial and induction of
mesenchymal phenotypes, enhancing tumor cells motility, invasion,
and consequently the ability to disseminate to the metastatic sites [2].
Metastatic melanoma, treated with standard conventional chemo-
therapy, has been historically associated with poor outcomes.
Currently, targeted therapy using specific small-molecule inhibitors
against the RAS–RAF–MEK–ERK pathway, which is hyperactivated
in more than 50% of melanomas (i.e. BRAF and MEK inhibitors) or
immunotherapy using monoclonal antibodies against immune
checkpoints (i.e. anti-CTLA4 and anti-PD-1/PD-L1) have shown
remarkable clinical efficacy with a significant improvement of overall
survival in patients with advanced or metastatic disease [3,4].
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and the serious autoimmune-related toxic effects induced by
checkpoint inhibitors [6] remain major problems. Beside these
therapies, radiotherapy is also proposed for the management of
melanoma [7]. For many years, melanoma was thought to be a
radioresistant tumor. Nevertheless, recent studies have demonstrated
the effectiveness of external photon-beam radiotherapy in melanoma
treatment such as stereotactic radiosurgery and/or radiotherapy for
patients with brain or bone metastases [8]. One of the most important
features of melanoma is the presence of melanin pigments. Two
major types of melanin are synthesized in melanocytes: the black-
brown melanin called eumelanin and the yellow-red one called
pheomelanin. These pigments are produced and stored within
specific membrane-enclosed lysosome-related organelles known as
melanosomes [9,10]. Melanins are indeed present into cytoplasm of
melanocytes, within melanosomes, but also in the extracellular space,
as free “naked melanin” called melanocore [11]. It is worth
mentioning that melanins can reduce response to radiotherapy and
chemotherapy due to its scavenging capacity for reactive oxygen
species and drugs [12]. It has also been described that eumelanin is
predominantly expressed in primary lesions, whereas pheomelanin is
associated to the disease progression [13]. Using 123I-BZA2, a
melanin radiolabeled benzamide derivative, it has been noted that
about 45% of melanoma metastases are pigmented [14]. Thus,
melanins provide a perfect target for melanoma-selective internal
radionuclide therapy, mainly for advanced stage melanoma patients
who have progressed after all current therapies. Three main
approaches using directed radiolabeled agents to melanin or
melanogenesis-related proteins have been developed: radioimmu-
notherapy, radiolabeled peptides, and radiolabeled small-molecules
[15]. Radioimmunotherapy using β-emitting 188Rhenium-
monoclonal antibodies against the extracellular melanin has shown
clinical efficacy in relatively small number of patients with advanced
unresectable or metastatic melanoma [16]. Peptide analogues to α-
MSH (α-melanocytes-stimulating hormone) targeting the MC1R
(melanocortin-1 receptor) appears to be potentially useful for
targeting melanoma [17]. Nonetheless, the heterogeneous expression
level of MC1R and the considerable kidney uptake of these
radiolabeled-peptide analogues limit this approach. Radiolabeled
small-molecules, such as benzamide derivatives, are known to bind
melanin pigment, which induces their selective accumulation in
melanomas [18]. Indeed, Mier and colleagues have shown that 131I-
BA52, a radioiodinated benzamide, induces antitumor effects
associated with more than 2-year survival rate in 3 of 5 treated
patients with metastatic melanoma [19]. Our laboratory validated an
131I-labeled quinoxaline derivative molecule, N-(2-(diethylamino)
ethyl)-6-iodoquinoxaline-2-carboxamide dihydrochloride salt
(ICF01012), for its melanin specificity, high uptake and retention
in tumor cells, as well as its rapid clearance from non-target tissues
and antitumoral efficacy using 123I- 125I-labeled and non-
radiolabeled ICF01012 [20–24]. The use of different iodine isotopes
allows characterization studies without modifying the quinoxaline
structure. If molecular mechanisms by which External Beam
Radiation Therapy (EBRT) modulates invasion in preclinical models
are quite well described [25], there is no such data on the impact of
TRT. In our previous studies, we showed that [131I]ICF01012
reduces spontaneous lung metastases generated from subcutaneous
primary B16BL6 tumor [21], and that could be associated to the anti-
angiogenic effect of [131I]ICF01012 [23].Here, we extend our knowledge on the capacity of [131I]ICF01012
to modify metastatic potential of melanoma both in in vivo and in
vitro, 3D spheroid, cell culture models. Importantly, we showed that
[131I]ICF01012 significantly decreases the number and the size of
lung colonies in B16BL6 murine model as well as the expression of
pro-metastatic factor in both in vivo and in vitro models. Melanoma
xenografts treatment with [131I]ICF01012 increases the level of both
eumelanin and pheomelanin pigments, suggesting a global effect of
[131I]ICF01012 on melanogenesis.
Materials and Methods
Cell Culture and Cell Lines
Murine B16BL6 melanoma cell line was obtained from the
laboratory of Pr. Fidler (Houston, TX, USA). Murine B16F10,
human SK-MEL3 and SK-MEL28 melanoma cell lines were
purchased from the ATCC. SK-MEL28 cells were grown in MEM-
Glutamax (Invitrogen) with 10% FCS (Eurobio) and 4 μg/μl
gentamycin (Invitrogen). B16BL6, B16F10 and SK-MEL3 cell lines
were cultured as described [24].
Animal Models
Female Swiss nu/nu mice and male C57BL/6 J (6 weeks old) were
respectively purchased from JanvierLabs and Charles River Labora-
tories (France). All animal studies were carried out in accordance with
the “Guide for the Care and Use of Laboratory Animals” and were
approved by the local ethics committee (C2E2A) under the number:
CE64–12.
Tumor Establishment and Radiotherapy Protocols
The murine syngeneic B16BL6 tumors and the human SK-MEL3
xenografts were established and treated with [131I]ICF01012 as
previously described [24].
Tumor Collection
For melanin assays, tumors were excised, frozen in N2 and stored at
−80 °C during the radioactive decay (80 days; 10 times a half-life of
the iodine-131 isotope). Eumelanin and pheomelanin analyses were
realized as described [26]. For tumors immunofluorescence, western
blot and cell cycle analyses, mice were sacrificed between day one and
day eight post-intravenously injection of 18.5 MBq [131I]ICF01012.
Tumors were excised and frozen in N2 then stored at −80 °C for
western blot analysis and cell cycle study as described [24], or fixed in
10% neutral buffered formalin (Sigma) and stored in 70% ethanol for
immunofluorescence analysis.
Immunofluorescence
After deparaffinization and rehydration of the five μm-thick
sections of B16BL6 tumors, antigen retrieval was conducted by
incubating the slides in boiling antigen unmasking solution
(Vector Laboratories) for 30 min. Endogenous peroxidase was
quenched by incubation for 30 min in 0.3% H2O2, and non-
specific sites were blocked with Antibody (Ab) diluent buffer
(Dako) for 1 h at room temperature (RT). Slides were then
incubated overnight (ON) at 4 °C in Ab dilution buffer with
primary Ab. The following primary Abs were used: rabbit
monoclonal anti-N-cadherin Ab (1/200) and rabbit monoclonal
anti-vimentin Ab (1/200) both from Abcam. Isotype controls were
slides incubated with irrelevant normal rabbit IgG (Sigma). Slides
were washed twice with PBS, and incubated with fluorescence-
Figure 1. [131I]ICF01012 activates DNA damage responses and induces cell cycle arrest in B16BL6 in vivomodel. (A) The expression
of phospho-H2A.X (γH2A.X) Ser139, phospho-p53 (P-p53) Ser15 and p21 proteins were measured by western blot analysis in B16BL6
tumors excised from C57BL/6 J mice at day 1 (D1) and days 3 (D3) post-[131I]ICF01012 injection (n = 3 tumors per group). Actin was used
as a loading protein control. The expression level was evaluated as the ratio of γH2A.X, P-p53 and p21 protein densities between non-
treated tumors (NT) and [131I]ICF01012 treated tumors (ICF). *P b .05; ***P b .001. (B) Cell cycle analysis of B16BL6 tumors excised at
day 1 (D1), days 3 (D3) and day 8 (D8) post-[131I]ICF01012 injection (D1, D8 NT and ICF: n = 3 tumors per group; D3 ICF: n = 3 tumors per
group, D3 NT: n = 2). Histograms mean % of cell population ± SD *P b .05; **P b .01,***P b .001; when compared treated tumors
(ICF) with their respective non-treated tumors (NT).
1444 [131I]ICF01012 reduces melanoma invasion Akil et al. Translational Oncology Vol. 12, No. 11, 2019conjugated secondary Ab to rabbit IgG (1/500; Invitrogen) for 1 h
at RT. Nuclei were stained with DAPI (0.1 μg/mL; Sigma). After
slide mounting with Vectashield, emitting fluorescence was
detected using Axio Imager 2 microscope (Zeiss), and analyzed
with ZEN software (Zeiss).
Lung Histological Examination and Colonization Analysis
Fixed lungs were embedded in paraffin, sections of four μm
thickness were realized and tissues were stained with hematoxylin-
phloxin saffron (HPS). The morphology of tumor cells and
adjacent tissue were then analyzed. After a two-dimensional lung
surface reconstruction (NIS-Element software, Nikon), lung
metastases areas were quantified with NIS-Analysis software
(Nikon).
Spheroid Culture and [131I]ICF01012 Irradiation Protocol
To generate melanoma cell spheroids, cells were seeded at a
density of 1000 cells/well, in 96-well non-adherent plates
(ThermoFisher), with a final volume of 100 μl/well of complete
cell culture medium supplemented with 0.5% methylcellulose
(Bio-techne). At day 6 of culture, each spheroid was irradiated
with 37 kBq of [131I]ICF01012/100 μl of cell culture medium
(without FCS) or with medium alone for control. After 1 h of
incubation, the irradiation medium was removed and replaced by
a complete medium supplemented with 0.5% methylcellulose.
Spheroids were then incubated for a various periods of time
ranging from 1 h to 72 h.Uptake Analysis
One hour post-irradiation, medium was removed and spher-
oids were washed twice, in wells, with PBS. Spheroids were then
taken in 100 μl of PBS and distributed at a rate of three
spheroids/tube. Activity was measured by 1480 Wizard Gamma
Counter (Perkin Elmer) during 1 minute (min) and was
normalized to the blank.
Colony Forming Assay
Twenty-four hours post-irradiation, 60 spheroids/condition were
collected and centrifuged. Supernatants were removed and spheroids
were dissociated with 500 μl collagenase IV (0.2%; Sigma) during 30
min at 37 °C. Cells were re-suspended, counted and seeded in 6 well
plates with a 2 mL final volume of complete culture medium. SK-
MEL3 cells were seeded at 7200 cells/well, SK-MEL28 at 1200 cells/
well, and B16BL6 and B16F10 at 400 cells/well. After 18 days of
incubation for SK-MEL3, 10 days for SK-MEL28 and 8 days for both
B16F10 and B16BL6 cells, medium was removed and colonies were
rinsed once with PBS. Colonies were then fixed by methanol absolute
during 3 min then revealed with 0.5% crystal violet solution. The
counting of colonies was realized using the ImageJ software. Plating
efficiency (PE) and survival fraction (SF) were determined as
described [27].
RT-qPCR Analysis
SK-MEL-3 spheroids were collected at 1 h and 4 h post-[131I]
ICF01012 irradiation (60 spheroids/time/condition), frozen in N2
Figure 2. [131I]ICF01012 decreases the expression of N-cadherin and vimentin in B16BL6 in vivo model. (A, B) Representative
fluorescence immunohistochemistry analysis of N-cadherin and vimentin expressions in B16BL6 tumors excised from C57BL/6 J mice 3
days post-[131I]ICF01012 injection (n = 3 tumors per group). Five μm-thick sections from non-treated (NT) and [131I]ICF01012 treated
tumors (ICF) were stained with anti-N-cadherin rabbit mAb (A) or anti-vimentin rabbit mAb (B) and revealed with Alexa fluor-488
conjugated fluorescent secondary antibodies (green). Nuclei were counterstained with DAPI (blue). (C, D) Relative quantification of N-
cadherin expression (C) and vimentin expression (D) assessed by green fluorescent surface plot analysis. N-cadherin: magnification, x40;
scale bars, 20 μm. Vimentin: magnification x20; scale bars, 50 μm.
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extraction was performed (RNA Extraction Kit; Qiagen) and RNA
amounts were measured by spectrophotometry (MultiskanGo,
ThermoFisher). cDNA were synthesized from 100 ng of RNA
using Thermoscript kit (Fisher Scientific). Two reactions of
transcriptase reverse were realized by sample. Quantitative PCR
(qPCR) reactions were realized with Master Mix SybrGreen using
Applied BioSystems StepOne Plus device. Primers and conditions of
annealing are described in Supplementary Table 1. Results are
expressed according to ΔΔCT method after normalization by the
GAPDH housekeeping gene. Two qPCR are realized for each
transcriptase reverse reaction.Western Blotting
Western blot analysis was carried out as described [28]. Briefly,
after complete radioactive decay, tumor proteins were extracted
with urea buffer using GentleMACS Dissociator (Miltenyi
Biotec). Spheroid proteins were extracted with Cell lysis buffer
(Cell Signaling Technology). Thirty μg of tumor proteins, 20 μg
of murine spheroid proteins and 15 μg of human spheroid
proteins were separated by SDS-PAGE then transferred tonitrocellulose membranes (BioRad). The following primary Abs
were used: anti-phospho-H2A.X (S139) (1/2000), anti-phospho-
p53 (Ser15) (1/1000), anti-MITF (1/1000) from Cell Signaling
Technology, anti-p21 (1/1000; Santa Cruz Biotechnology), anti-
N-cadherin (1/5000), anti-vimentin (1/4000) from Abcam, and
anti-Actin (1/10000; Sigma).
Statistical Analyses
Statistical analyses were performed with XLStat software (Addin-
soft, VA, USA) and StatView software (Abacus concepts) using
Student's t test for animal experiments, RT-qPCR analysis, cell cycle
analysis and a one-way analysis of variances (ANOVA) for in vitro
experiments, pigmentation analysis.
Results
Effects of [ 131I]ICF01012 on DNA Damage Response and Cell
Cycle in B16BL6 Melanoma Murine Model
To validate the antitumor effect of [131I]ICF01012, we first
examined the expression of specific proteins involved in DNA damage
response (γH2A.X; phospho-p53) and cell cycle control (p21) in
tumors extracted 1 day and 3 days after irradiation. Consistent with
Figure 3. [131I]ICF01012 reduces clonogenic capacity of melanoma spheroids in a cell pigmentation-dependent manner. (A)
Uptake analysis of [131I]ICF01012 in pigmented B16F10, B16BL6, SK-MEL3 and non-pigmented SK-MEL28 melanoma spheroids. Uptake
analyses were realized after 1 h of spheroid incubation with [131I]ICF01012. Histograms mean % of the uptake of the administrated dose
(1 μCi) ± SEM of three independent experiments. *P b .05; ***P b .001; when compared with SK-MEL28 spheroids uptake. (B) Effect of
[131I]ICF01012 on clonogenic capacity of melanoma spheroids. Colony forming assays of B16BL6, B16F10, SK-MEL3 and SK-MEL28
melanoma spheroids 24 h post-[131I]ICF01012 irradiation (ICF). Histograms mean % of survival fractions ± SEM of three independent
experiments. *P b .05; ***P b .001; when compared with respective controls (NT).
1446 [131I]ICF01012 reduces melanoma invasion Akil et al. Translational Oncology Vol. 12, No. 11, 2019our previous findings [24], [131I]ICF01012 irradiation does not
induce significant modifications on γH2A.X Serine 139 (Ser139)
protein levels, after 1 day and 3 days of treatment (Figure 1A).
However, it is worth mentioning that the basal γH2A.X expression
level was high in the control tumors. In contrast, the expression
level of phosphorylated p53 protein at Ser15 increased significantly
in treated group compared to the non-treated group, after 1 day
(1.7-fold increase) and 3 days (1.6-fold increase) post-irradiation
(Figure 1A). The activation of p53 protein led to an increase of p21
protein expression, after 1 day (5-fold increase) and 3 days (4.8-fold
increase) post-irradiation (Figure 1A). We subsequently analyzed
cell cycle modifications in B16BL6 tumors after 1 day and 8 days
post-[131I]ICF01012 injection. In accordance with our previous
studies [23,24], we showed that [131I]ICF01012 significantly
decreased the proportion of cells in G1 phase and induced G2/M
phase arrest in these wild-type p53 B16BL6 tumor cells (Figure
1B).[ 131I]ICF01012 Alters the Expression of Epithelial-Mesench-
ymal Transition-Like Markers in B16BL6 Melanoma Murine
Model
It is well known that EMT-like is an essential biological event for
melanoma tumor invasion and metastasis. For that, we next
investigated whether [131I]ICF01012 treatment altered EMT-like
in B16BL6 melanoma-bearing mice by immunohistochemical
analysis. The expression of two EMT-like markers, the Neural
cadherin (N-cadherin) and the vimentin, was assessed. Interestingly,
3 days post-irradiation, a reduction of mesenchymal N-cadherin
(Figure 2, A and C) and vimentin (Figure 2, B and D) markersexpression was observed when compared irradiated tumors to the
non-treated tumors.In Vitro Efficacy Study of [ 131I]ICF01012 on Murine and
Human Melanoma Tumor Spheroid Models
In order to study precisely the mechanisms underlying the effect of
[131I]ICF01012 treatment on invasion and antitumor efficacy, we
established 3D in vitro spheroid models that mimic in vivo tumor
mass architecture. First, we confirmed the uptake and the efficacy of
[131I]ICF01012 in murine (B16F10 and B16BL6) and in human
melanoma spheroid models (SK-MEL3 and SK-MEL28). As shown
in Figure 3A, the uptake of [131I]ICF01012 is depending on cellular
pigmentation in spheroids. Indeed, in comparison with the non-
pigmented SK-MEL28 spheroids, [131I]ICF01012 uptake is signif-
icantly higher in well pigmented murine spheroids (B16BL6 and
B16F10) as well as in human less pigmented SK-MEL3 spheroids.
The efficacy of [131I]ICF01012 treatment where then determined
using the clonogenic survival assay. Figure 3B demonstrates that
[131I]ICF01012 treatment reduces clonogenic capacity of all
pigmented melanoma spheroids except for the non-pigmented SK-
MEL28 spheroids. Compared to the non-treated spheroids, the
survival fractions of irradiated spheroids were respectively 38.2% and
55.9% for both B16BL6 and B16F10 spheroids, 65.2% for SK-
MEL3 spheroids and 105.6% for the non-pigmented SK-MEL28
spheroids.
Secondly, the effects of [131I]ICF01012-induced DNA damage
response and cell cycle arrest were determined using western blot
analysis. Figure 4 shows that except for the non-pigmented SK-
MEL28 spheroids, [131I]ICF01012 induces DNA damage response
Figure 4. [131I]ICF01012 activates DNA damage responses in pigmented melanoma spheroids. (A, B) The capacity of [131I]ICF01012
to induce DNA damage signaling pathway in melanoma spheroids was assessed by western blot analysis using antibodies specific to
γH2A.X (Ser139), P-p53 (Ser15) and p21 proteins. The pigmented murine B16BL6 and B16F10 spheroids (A), as well as the human
pigmented SK-MEL3 and non-pigmented SK-MEL28 melanoma spheroids (B) were irradiated with [131I]ICF01012 and harvested at
indicated times. Actin was used as a loading protein control. The fold induction was evaluated as the ratio of γH2A.X, P-p53 and p21
protein densities between non-treated (NT) and [131I]ICF01012 treated spheroids (ICF).
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(Ser139) and phospho-p53 (P-p53) (Ser15) proteins expression levels
were enhanced 30 min post-irradiation in the two murine B16BL6
(3.1-fold increase for γH2A.X and 2.3-fold increase for P-p53) as
well as B16F10 (1.8-fold increase for γH2A.X and 1.9-fold
increase for P-p53) spheroids, and remained higher than the
controls up to 24 h (Figure 4A). [ 131I]ICF01012 also increases the
expression levels of these two DNA damage response markers, after
1 h of irradiation (2-fold increase for γH2A.X and 1.2-fold increase
for P-p53) in SK-MEL3 human spheroids, and remained higher
than the controls up to 72 h (Figure 4B). It is well known that p21
protein is an essential factor for the p53-mediated cell cycle arrest in
cells with damaged DNA. As shown in Figure 4A, phosphorylation
of p53 enhances the expression of p21 protein in wild-type p53
B16BL6 and B16F10 spheroids. The p21 protein was not detected
in mutant p53 SK-MEL3 spheroids (data not shown). Taken
together these data suggest that [131I]ICF01012 mediates its
antitumor effect by inducing DNA damage and cell cycle arrest
coupled with reduced clonogenic capacity of pigmented melanoma
spheroids.[ 131I]ICF01012 Reduces the Acquisition of EMT-Like Phe-
notype
To investigate the impact of [131I]ICF01012 on spheroid
models, EMT-like-related genes expression levels were measured
in SK-MEL3 spheroids, using RT-qPCR analysis (Figure 5).
Importantly, we showed an early 20% decrease of SPARC
transcription 1 h post-irradiation. In addition, the expression
levels of two MITF transcription regulatory factors, BRN2 and
ZEB2, were respectively decreased at 1 h (30% fold-decrease)
and 4 h (15% fold-decreased) post-irradiation. Concomitantly, we
observed a significant 15% MITF expression decrease. The other
studied genes did not show significant transcription modification
(Supplementary Figure 1). Western blot analysis of [131I]
ICF01012 treated spheroids afforded additional evidence to
support [131I]ICF01012-mediated reduction of EMT-like. In-
deed, [131I]ICF01012 decreases the expression levels of the two
EMT-like markers N-cadherin and vimentin in, BRAF wild-type,
B16BL6 and B16F10 murine spheroid models. The decreased
expression levels of N-cadherin and vimentin were detected from
30 min post-irradiation in B16F10 spheroids (1.28 fold-decreased
Figure 5. EMT-like-related genes expression in SK-MEL3
irradiated spheroids. RT-qPCR analysis of EMT-like-related
genes expression in total RNA extracted from human melanoma
SK-MEL3 spheroids at 1 h and 4 h post-[131I]ICF01012 irradiation.
Target genes expression were normalized to the housekeeping
GAPDHmRNA. The gene expression in treated spheroids (ICF) was
compared to that of non-treated spheroids (NT) (fold-regulation).
Results are presented as means Relative Quantification ± SEM of
three independent experiments.*P b .05.
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remained lower than the controls up to 24 h (Figure 6A). The
same results were obtained for the B16BL6 spheroids (data not
shown). [ 131I]ICF01012 irradiation of V600EBRAF-mutated SK-
MEL3 spheroids appears to be less effective. Indeed, the
expression levels of N-cadherin and vimentin proteins decreased
slightly during the 48 h post-irradiation, then increased at 72 hFigure 6. [131I]ICF01012 decreases the expression of EMT-like ma
vimentin were analyzed by western blot in total cellular protein extrac
(ICF) or not (NT) with [131I]ICF01012 and harvested at indicated times.
evaluated as the ratio of N-cadherin and vimentin protein densities b
total cellular protein extracted from SK-MEL3 spheroids treated (ICF
Actin was used as a loading protein control. The fold induction was e
spheroids.(1.62 fold-increase for N-cadherin and 1.6 fold-increase for
vimentin) suggesting a radioresistance sign of SK-MEL3 spheroids
to the [131I]ICF01012-induced EMT-like reduction (Figure 6B).
Although the specific role of MITF in EMT-like remains not fully
understood, the relationship between the phenotype switching of
melanoma cells and the level of MITF expression has been well
reported. Indeed, it has been described that melanoma tumor cells
with high MITF expression are differentiated and mostly
proliferating cells, whereas those with low MITF expression are
further invasive and less proliferating cells [29]. It is worth
mentioning that [131I]ICF01012 decreases the expression of
MITF at mRNA (Figure 5) and protein levels (Figure 6C) in SK-
MEL3 spheroids confirming the radioresistance signs of these
BRAF-mutant spheroids to [131I]ICF01012-mediated reduction
of EMT-like.
[ 131I]ICF01012 Modifies Pigmentation
In order to investigate the effect of the [131I]ICF01012 treatment
on melanogenesis, the expression of the tyrosinase protein was
evaluated in human SK-MEL3 spheroids. Figure 7A shows that [131I]
ICF01012 enhances the expression levels of the tyrosinase at 48 h and
72 h post-irradiation. Accordingly, we showed that [131I]ICF01012
treatment is accompanied by an increased level of total melanin from
5.8 to 8.4 μg/mg in SK-MEL-3 human xenografts (Figure 7B).
Furthermore, eumelanin (Figure 7C) and pheomelanin (Figure 7D)
were significantly increased with a constant ratio of pheomelanin/
eumelanin (Figure 7E).
[ 131I]ICF01012 Decreases Lung Colonies in B16BL6 Mela-
noma Murine Model
We have previously shown that [ 131I]ICF01012 induced
significant slowing of tumor growth and decreased spontaneous
lung metastases in melanoma preclinical models [21,23,24,30]. Torkers in melanoma spheroids. The expression of N-cadherin and
ted from B16F10 (A) and SK-MEL3 (B) spheroids that were treated
Actin was used as a loading protein control. The fold induction was
etween NT and ICF spheroids. (C) Western blot analysis of MITF in
) or not (NT) with [131I]ICF01012 and harvested at indicated times.
valuated as the ratio of MITF protein densities between NT and ICF
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and to limit distant organ invasion, we examined here the efficiency of
[131I]ICF01012 on pigmented B16BL6 melanoma lung colonies. As
shown in Figure 8, A and B, 13 days after intravenous injection of
18.75 MBq [131I]ICF01012, a significant decrease of lung weight
between control and treated groups (257 ± 59 vs 174 ± 41 mg,
respectively) was observed. To consolidate this result, a quantification
of metastasis areas was performed on random HPS lung slices (Figure
8, C–E). In control group, the median of the lung invasion was
12.65%. [131I]ICF01012-TRT decreased significantly the size of
metastases and the median of invasion did not exceed 1% of the lung
surface (i.e. 0.75%; Figure 8D). Lung colonies-adjacent tissue was
evaluated and no macroscopic changes were observed after [131I]
ICF01012 treatment.
Discussion
The functional consequences of radiotherapy on tumor aggressiveness
remain a matter of debate, with results from preclinical models being
different to those observed in clinical studies. Indeed, EBRT was
often associated with an enhancement of metastatic processes in
experimental in vitro and in vivo studies, while the effects of EBRT
on patients are associated with favorable survival without progression
[25]. In this study, we addressed some questions about the impact of
TRT on invasion and metastatic dissemination processes. We have
previously reported a regression of spontaneous melanoma metastases
in B16BL6 model [21]. Here we observed a decrease of melanoma
lung colonies, after intravenous injection of cells, following TRT.
Taken together these findings suggest that [131I]ICF01012 modifies
metastatic processes presumably by the reduction of angiogenesis, cell
motility and invasion. We indeed showed a decrease of vascular
endothelial growth factor as well as of small vessels in irradiated
tumors [23]. The reduction of metastatic invasion induced by [131I]
ICF01012 should be related to EMT-like; indeed the expression of
N-cadherin and vimentin, two proteins involved in the EMT, were
reduced in tumors after [131I]ICF01012 treatment. Besides, we
demonstrated that [131I]ICF01012, by remaining a long time in the
tumor, induces a sustained DNA damage response and cell cycle
blockade as evidenced by the G2/M arrest and the increased amount
of phosphorylated p53 protein and its downstream target p21
protein. [131I]ICF01012 seemed also able to modify the second part
of metastatic process, which is the homing of circulating cells to target
tissues. Our findings indeed showed a significant decrease of lung
colonies, suggesting that [131I]ICF01012 can kill circulating
pigmented melanoma cells and/or modify their program to reduce
their extravasation and proliferation in lungs.
In order to investigate specifically the effect of [131I]ICF01012 on
melanoma metastasizing capacity, we developed 3D cell culture
models and demonstrated their relevance for TRT study. We showed
that [131I]ICF01012 can penetrate spheroids in a cell pigmentation-
dependent manner and provokes DNA damage and cell cycle arrest,
only in pigmented ones. These findings were in line with in vivo
results [30] and validated spheroids to further explore TRT-induced
mechanisms. Indeed, in the murine BRAF wild-type B16BL6 and
B16F10 melanoma spheroids, we showed an early and continuous
decrease of EMT-like markers, post-TRT treatment. In the human
V600EBRAF-mutant SK-MEL3 spheroids, TRT-induced EMT-like
reduction was less pronounced. SK-MEL3 cells are derived from a
metastatic lymph node and we can assume that these cells are in an
invasive state. Indeed, at the mRNA level, [131I]ICF01012 inducedan early and transitory decrease of SPARC transcription, a coding
gene for a secreted extracellular matrix-associated protein that is
involved in the EMT-like, by facilitating melanoma cell spreading
specifically to the lung [31]. [131I]ICF01012 treatment also
transiently modified the expression level of MITF and its
transcription activator ZEB2. MITF is a key transcription factor
involved in proliferation and invasion of melanoma cells. Its
regulation obeys to a complex rheostat: an MITFlow/ ZEB2low
expression favors invasion, characteristic of a mesenchymal state, and
an MITFhigh/ ZEB2high expression favors proliferation and differen-
tiation, characteristics of an epithelial state [32]. Besides, MITF
expression levels are precisely regulated in melanoma cells to ensure
their survival, because a very low level of MITF expression leads to cell
death and a too high level induces cell cycle arrest and differentiation
[33]. Additionally, Wellbrock et al. [33] have shown that proliferation
in V600EBRAF melanoma cells is regulated through the activation of
MITF promoter by the oncogenic V600EBRAF/ERK/BRN2 pathway
with a MITF-BRN2 reciprocal repression. In the V600EBRAF
spheroids, 4 h post-irradiation, [131I]ICF01012 treatment of SK-
MEL3 spheroids resulted in a transient decrease in MITF mRNA
expression as well as its transcriptional activator ZEB2, suggesting a
form of radioresistance through an increase of invasiveness, according
to Caramel et al. [32]. But, the early reduction of BRN2 (1 h after
treatment) precedes MITF expression decrease and could be
interpreted as a limitation of invasion and support the idea of cell
death induced by a very low MITF expression in the early time
following treatment in this V600EBRAF model. On the other hand,
we did not find significant transcription modifications for other
EMT-like markers as E-cadherin (epithelial state) or N-cadherin
(mesenchymal state), neither for stemness genes as OCT4, prolifer-
ation genes as PCNA, or for genes involved in differentiation as
tyrosinase (TYR). Nevertheless, in the same model, we described a
first slight decrease of N-cadherin and vimentin protein expressions
followed however by an increase at 72 h post-irradiation. These
results suggest a post-translational impact of [131I]ICF01012 and an
initial decrease of EMT-like followed by a form of radioresistance in
these BRAF-mutant spheroids. We also observed an early decrease of
MITF protein at 4 h post-irradiation, confirming the RT-qPCR
results, followed however by an increase of tyrosinase protein
expression, which suggests an enhancement of cell differentiation.
Accordingly, we showed that [131I]ICF01012 increases pigmentation
in human SK-MEL3 xenograft model, confirming the hypothesis of
differentiation induction in the human BRAF-mutant melanoma
cells after [131I]ICF01012 treatment. Despite the specificity of [131I]
ICF01012 for pigmented melanoma and the inefficacy of [131I]
ICF01012 on non-pigmented M3Dau melanoma xenografts [20],
the property of this TRT to induce melanin synthesis should
contribute to cure poorly pigmented lesions. An interesting point will
be to assess the effect of TRT on mixed metastatic lesions i.e.
pigmented and non-pigmented ones and to observe if an abscopal
effect will occur.
Conclusions
We provide here additional proof on the pertinence of [131I]
ICF01012-TRT approach for pigmented metastatic melanoma. We
thus demonstrated that [131I]ICF01012 reduces tumor metastatic
capacity by modifying the expression of EMT-like markers. We also
proved the relevance of a spheroid model for this type of study.
However, the precise regulation remains unclear. In B16 mouse
1450 [131I]ICF01012 reduces melanoma invasion Akil et al. Translational Oncology Vol. 12, No. 11, 2019melanoma model, [131I]ICF01012 decreases the expression of the
EMT-like main proteins N-cadherin and vimentin. In human
melanoma V600EBRAF model, the effects of [131I]ICF01012 are
more puzzling: there are arguments for an early efficiency associatedwith a differentiation (pigmentation) but the question of an induction
of radioresistance arises. The increase of pigmentation can also be
assimilated to a defense mechanism against the radiation, which could
be beneficial in the hypothesis of a repeated treatment. Further
Figure 8. [131I]ICF01012 reduces lung colonization in B16BL6 syngeneic model. C57BL/6 J mice were injected intravenously into the
tail vein with 1.5 × 105 B16BL6 melanoma cells to induce lung colonies. After 7 days, mice were non-treated (NT) or received an
intravenous injection of 18.5 MBq [131I]ICF01012 (ICF) (n = 10 mice per group). Mice were sacrificed on day 13 post-[131I]ICF01012
injection and lungs were excised and weighed. (A) Histograms mean lungs weight from each group ± SD *P b .05. (B) Representative
images of lungs from each group. (C) Representative HPS histological stained sections of lungs from each group (nodules are indicated
by arrows; Scale bars, 200 μm). (D) Scattergram representing the percentage of B16BL6 lung invasion from each group. *P b .05. (E)
Representative two-dimensional reconstructions of lungs surface from each group (nodules are indicated by arrows).
Translational Oncology Vol. 12, No. 11, 2019 [131I]ICF01012 reduces melanoma invasion Akil et al. 1451investigations, in syngeneic spontaneous melanoma model or in
patients-derived xenografts, are mandatory to better understand the
precise mechanisms that underlie the effects of [131I]ICF01012-TRT.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2019.07.015.
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